$SOPH

SOPHiA GENETICS SA

SOPHiA GENETICS is a cloud-native healthcare software company that provides data analytics for healthcare professionals and life sciences researchers, including hospitals, clinical and research laboratories, and biopharmaceutical companies. Its SOPHiA DDM platform uses AI to standardize and analyze genomic and other digital health data, helping users generate insights for diagnosis, treatment selection, disease monitoring, and drug development. Customers generally test their own samples and use the platform to analyze pseudonymized and de-identified data. The company’s clinical offerings include genomic applications across oncology and other disease areas, the Alamut suite of mutation interpretation software, and SOPHiA CarePath for multimodal analysis. Its biopharma products include SOPHiA Insights, SOPHiA Trial Match, SOPHiA CDx, and SOPHiA Awareness. SOPHiA GENETICS makes money primarily through pay-per-use access for clinical customers, along with other platform access models, and commercializes its products directly and through distributors and collaborations. Its principal executive office is in Rolle, Switzerland.

No enriched coverage for $SOPH in the last 7 days.

$278K
$205K
Van Well Daan
75%
See all $SOPH insider activity →
Med

SOPHiA GENETICS Earnings Call Signals Strong Momentum

SOPHiA GENETICS (SOPH) reported Q3 revenue of $24.3M, up 25% YoY, with record analysis volumes and improved adjusted EBITDA loss of $6.1M. U.S. revenue grew 41%, and new customer wins were highlighted. Challenges include FX pressure and implementation delays.

Muken Ross purchased $137K of SOPH

Muken Ross (Chief Executive Officer) purchased 20,000 shares of SOPHiA GENETICS SA (SOPH) at $6.86 ($0.14M total) on 2026-11-06.

SOPH sentiment & insider activity

Recent SOPH coverage spans earnings, insider activity and financial news.

In the last 30 days, SOPH insiders filed 8 SEC Form 4 transactions — 2 purchases ($278K) and 6 sales ($205K). The most active reporter was Van Well Daan, Chief Legal Officer, with 2 filings. 75% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving SOPH

  • Improving top‑line and loss metrics may lift the stock, though foreign‑exchange headwinds and execution backlog temper upside.

    tipranks.com · Nov 15, 2026

  • The insider purchase signals confidence from management and may create modest buying pressure.

    SEC EDGAR · Nov 9, 2026

  • Insider purchase suggests confidence and may create modest buying pressure.

    SEC EDGAR · Nov 9, 2026

  • Guidance reaffirmation plus improving adjusted EBITDA loss and retention metrics likely supports the stock, but the continued loss outlook caps upside.

    finance.yahoo.com · Nov 3, 2026

  • The earnings beat on revenue and improved adjusted EBITDA loss may support modest upside, but ongoing net loss tempers enthusiasm.

    SEC EDGAR 6-K · Nov 3, 2026

AlphAI scores every news story that mentions SOPH with an AI model for sentiment and relevance, and aggregates insider trades from SOPHiA GENETICS SA's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $SOPH

Score

SOPHiA GENETICS Q3 Earnings Call Highlights

SOPHiA GENETICS reported 551 core genomics customers, up from 488 a year earlier, with 30 new logos signed. CFO George Cardoza highlighted net dollar retention at 118% and annualized revenue churn below 1%. Growth was seen in HemOnc, Rare Disorders, and Solid Tumor testing, with MSK-IMPACT Flex adoption driving Solid Tumor growth. Liquid biopsy volume doubled year-over-year.

$SOPHMedEarnings

SOPHiA GENETICS SA (SOPH): Financial results for Q3 2026

SOPHiA GENETICS SA (SOPH) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 SOPHiA GENETICS Reports Third Quarter 2026 Results BOSTON, United States and ROLLE, Switzerland, November 3, 2026 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September

SOPHiA, Myriad Partner on Prostate Cancer Companion Diagnostic Development

SOPHiA GENETICS and Myriad Genetics collaborate to develop a prostate cancer companion diagnostic using PrGIS, a biomarker for homologous recombination deficiency. Myriad's MyChoice CDx test, currently used in ovarian cancer, will be expanded for prostate cancer. The partnership aims to evaluate PrGIS in clinical trials and enable global laboratory testing. Myriad will present research at the European Society for Medical Oncology Congress 2026.

$SOPHMedAI 8/10

SOPHiA GENETICS (SOPH) Q2 2026 Earnings Call Transcript

SOPHiA GENETICS SA (SOPH) reported Q2 2026 revenue of $23.3 million, up 27%, and an adjusted EBITDA loss of $8.8 million. Platform analysis volume rose 22% to 115,000 patient analyses. Management raised full-year revenue guidance to $94 million to $96 million and reaffirmed adjusted EBITDA loss of $29 million to $32 million, citing U.S. in-house testing demand and biopharma growth.

Biotech Stocks At 52-Week Highs - UFPT +25%, INFU +33%, SOPH +20% On Q2 Reports, REPL, PBLS

Biotech stocks hit 52-week highs Aug 4, 2026 after Q2 results or regulatory updates. UFP Technologies (UFPT) rose over 25% to $338.70, reporting Q2 net income $20.9M and sales $174M. InfuSystem (INFU) gained 33% to $12.49 on $36.9M Q2 revenue and 2026 guidance. Replimune (REPL) jumped to $13.86 after a favorable BLA opinion. SOPHiA (SOPH) rose to $6.98 with $23.3M Q2 revenue and 2026 outlook. Parabilis (PBLS) reached $36.69.

Related tickers